ClinVar Miner

Submissions for variant NM_001100.3(ACTA1):c.419C>G (p.Ala140Gly) (rs1435160117)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000685030 SCV000812501 pathogenic Nemaline myopathy 3 2018-08-27 criteria provided, single submitter clinical testing This sequence change replaces alanine with glycine at codon 140 of the ACTA1 protein (p.Ala140Gly). The alanine residue is highly conserved and there is a small physicochemical difference between alanine and glycine. This variant is not present in population databases (ExAC no frequency). This variant has been observed to be de novo in an individual affected with myofibrillar myopathy (Invitae). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C55"). The observation of one or more missense substitutions at this codon (p.Ala140Pro and p.Ala140Asp) in affected individuals suggests that this may be a clinically significant residue (PMID: 12921789, 19562689). For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.